Alteplase Used in a Child with an Acute Ischemic Stroke by Chaudhary, Shah Nawaz et al.
Rowan University 
Rowan Digital Works 
Stratford Campus Research Day 25th Annual Research Day 
May 6th, 12:00 AM 
Alteplase Used in a Child with an Acute Ischemic Stroke 








Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day 
 Part of the Cardiovascular Diseases Commons, Neurology Commons, Pediatrics Commons, and the 
Pharmaceutical Preparations Commons 
Let us know how access to this document benefits you - share your thoughts on our feedback 
form. 
Chaudhary, Shah Nawaz; Espinosa, James; Lucerna, Alan; and Richards, Adam, "Alteplase Used in a Child 
with an Acute Ischemic Stroke" (2021). Stratford Campus Research Day. 8. 
https://rdw.rowan.edu/stratford_research_day/2021/may6/8 
This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital 
Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of 
Rowan Digital Works. 
Alteplase Used in a Child with an Acute Ischemic Stroke 
Shah Nawaz Chaudhary DO, James Espinosa MD, Alan Lucerna DO, Adam Richards MD 
Emergency Medicine Residency and Department of Emergency Medicine, Rowan University, SOM 
References: 
1. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. 
Neurotherapeutics. Ovbiagele, B., & Nguyen-Huynh, M. N. 3, 2011, The journal of the American 
Society for Experimental NeuroTherapeutics, Vol. 8, pp. 319–329. 
2. 2. Pediatric stroke: a review. Tsze, D. S., & Valente, J. H. 2011, Emergency Medicine International 
2011, Vol. 2011, p. 734506. 
3. 3. Diagnostic pitfalls in paediatric ischaemic stroke. . Braun KP, Kappelle LJ, Kirkham FJ, Deveber G 
Dev. 12, December 2006, Med Child Neurology , Vol. 48, pp. 985-90. 
4. 4. Time lag to diagnosis of stroke in children. Gabis LV, Yangala R, Lenn NJ. 5, s.l. : Pediatrics , 2002, 
Vol. 110. 924-928. 
5.  Tissue Plasminogen Activator for Acute Ischemic Stroke. Study, The National Institute of 
Neurological Disorders and Stroke rt-PA Stroke. 1995, The New Englend Journal of Medicine, Vol. 
333, pp. 1581-1588. 
6.  Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. Werner Hacke, M.D., et. 
al. 2008, The New England Journal of Medicine, Vol. 359, pp. 1317-1329. 
Discussion: 
Pediatric strokes are a relatively rare (1 to 2.5 per 100,000 children in the United States per year) 
compared to adult strokes (up to 970 per 100,000 adults between ages 65 and 74 in the Unities States 
per year) (1). While strokes in adults are commonly linked to risk factors such as hypertension, 
hyperlipidemia, and diabetes, pediatric stroke risk factors include congenital heart disease, sickle cell 
disease and leukemia (2). The patient in this case study had a history of HLHS, a ductal dependent 
malformation that is universally fatal if not surgically palliated shortly after birth. Our patient had a 
three-stage procedure that included the Norwood, Glen, and Fontan surgeries, which have been shown 
to increase survival to 90% at 18 years of age. Unfortunately, despite improved mortality post-fontan, 
almost all patients experience complications including thromboembolic events.  
 
As the medical community continues to create and provide innovative treatment modalities to patients 
with illnesses that have historically had poor prognostic outcomes, such as complex congenital heart 
anomalies, the Emergency Department is faced with new and rare pathologies that can require rapid 
diagnosis and treatment, including ischemic strokes in children. This changing landscape presents 
challenges. One study showed clinicians diagnosing stroke in a pediatric patient as late as 3 months later 
(3) and another study showed delay in brain imaging from symptom onset as late as 7.2 hours (4). The 
patient discussed in this case study presented to a community hospital with adult comprehensive stroke 
services but without pediatric subspecialty coverage. The clinicians in this case-study utilized their 
knowledge of stroke care in adults and applied it to this pediatric patient. In less than 10 minutes an 
emergency physician evaluated the patient, in less than 25 minutes the patient had CT scan of his head, 
in less than 45 minutes the CT scan results was interpreted and in one hour and thirteen minutes of 
arrival to the hospital (approximately one hour and 43 minutes from symptoms onset) the patient 
received tPA. By the time the patient arrived to the receiving children’s hospital, he was able to move 
his left upper extremity and had near complete neurological recovery after mechanical thrombectomy.  
 
The current FDA approval of tPA in adult patients with strokes is supported by the NINDS rt-PA trial and 
ECASS III trials. Although it is reasonable to consider tPA in children based on these studies, such 
treatment is off-label extrapolation. The fibrinolytic system is a dynamic process that continues to 
develop following birth and there are qualitative and quantitative differences in plasminogen and 
plasminogen activator inhibitors in infants, children, and adults (4). These differences could affect 
optimal tPA dosing in children. A major complication of administering tPA is bleeding, including 
symptomatic intracranial hemorrhage (sICH) which increases morbidity and mortality. The rate of 
symptomatic intracranial hemorrhage was 6.4% in the NINDS trial and 2.4% ECASS III trial (5) (6). Of 
note, patients with ischemic stroke are at increased risk of spontaneous intracranial hemorrhage even 
without use of thrombolytics (6). Therefore, administering tPA in acute strokes is a balance between 
maximizing clot breakdown to enhance neurological recovery while minimizing risk of bleeding. The 
patient in this case study received an adult dose of tPA, did not suffer any adverse outcome and had 
improved neurological function, illustrating that there is a role of tPA in pediatric strokes, but optimal 






Pediatric strokes are relatively rare but result in death and lifelong disability if not appropriately 
identified and treated. Emergency physicians are faced with the challenge to rapidly identify and care 
for patients of any age presenting with strokes. Current treatment for pediatric strokes is based on 
clinical expertise, case studies, and extrapolation from adult trials. The problem with using adult trials to 
guide treatment in children is the fibrinolytic system in infants and children are different than that in 
adults Without evidence-based dosing guidance, children remain at risk of unintended consequences 
such as symptomatic intracranial hemorrhage and inadequate thrombolysis. The TIPS trial was the first 
multicenter, dose-adaptive, prospective treatment trial in acute pediatric strokes but it unfortunately 
lost funding due to lack of patient recruitment and other logistical issues (6). While another treatment 
trial is needed to test tPA’s efficacy and risk, this case study adds the growing literature of thrombolysis 
in pediatrics strokes.  
 
Abstract: 
Stroke, also known as cerebrovascular accident (CVA), is a neurological injury caused by 
inadequate brain perfusion due to either ischemia or hemorrhage. There is an abundance of 
literature on the management of ischemic strokes in adults and this has led to well defined 
diagnostic and treatment guidelines. However, the management of pediatric ischemic strokes is 
currently based on clinical experience of experts, recommendations of consensus guidelines, 
case studies and extrapolation from adult clinical trials. In this case report a pediatric patient 
suffering from an ischemic stroke is successfully treated with IV alteplase (tPA).  
Case Presentation:  
 A 15-year-old male was brought to the ED for difficulty speaking, left sided facial droop and left 
sided weakness. Last known normal was approximately 30 minutes prior to arrival. The patient 
had a past medical history of hypoplastic left heart syndrome (HLHS) surgically palliated via 
“fontan surgery on day 3, 6 months and 18 months of life”. The patient’s medications included 81 
milligrams aspirin every other day. Vital signs on arrival were a blood pressure of 119/62, heart 
rate of 84 beats per minute, respiratory rate of 20 breaths per minute, oxygen saturation of 93% 
on room air and oral temperature of 98.1F. The patient weighed 59.8 kilograms.  
 
On exam the patient was resting comfortably and in no acute distress. He was able to talk but 
had moderate dysarthria. He was awake, alert and oriented to person, place and time. He had a 
left upper and lower facial droop. He was unable to move his entire left upper extremity, 0/5 in 
strength. His left lower extremity was weak, 3/5 in strength. The patient’s NIH Stroke Scale was 
10 for left sided facial palsy, left upper extremity paralysis, left lower extremity weakness, and 
dysarthria. Remainder of his exam was unremarkable.  
 
Our patient underwent prompt neuro-imaging after establishing vascular access and 
documenting a blood glucose of 68. CAT scan of his head without contrast showed concern for 
hyperdense thrombus in the M1 segment of the right middle cerebral artery (MCA) [Figure 1] 
and the CT angiogram of the head and neck confirmed complete occlusion of mid to distal M1 
segment of right MCA with an intraluminal thrombus, which spanned approximately 8mm [Figure 
2, 3]. 
 
These results were discussed with the on-call neurologist and neurosurgeon at a local tertiary 
pediatric center who recommended administration of tPA and immediate transfer to their 
hospital. tPA was administered (.9 mg/kg/dose, 10% bolus over one minute as bolus and 
remainder over one hour as an infusion). When he arrived at the receiving hospital, a repeat 
neurological exam showed the patient regained 3/5 strength in his left upper extremity but still 
had a facial droop, dysarthria and left lower extremity weakness. The patient underwent a 
mechanical thrombectomy where the clot was successfully removed from the right MCA with a 
penumbra suction catheter. Post-suction angiography showed satisfactory flow in the right MCA. 
The patient was admitted to the ICU where his neurological exam significantly improved during 
his hospital stay. He regained 5/5 strength in all extremities and his dysarthria resolved but a 
mild left lower facial droop was still slightly visible when he smiled. The patient had a negative 
hypercoagulable workup. Bilateral upper and lower extremity venous ultrasounds were negative 
for deep vein thromboses. Transthoracic echocardiogram and cardiac MRI showed normal post-
fontan anatomy and physiology without signs of intracardiac thrombi or vegetations. The patient 
was started on anticoagulation (Lovenox). The patient had no incidence of bleeding or 
symptomatic intracranial hemorrhage (sICH). The patient remained stable and by hospital day six 




Figure 1:  CT Head without IV contrast showing the focal hyperdensity circled in 
red is known as the “hyperdense MCA sign”.  
Introduction: 
Stoke or cerebrovascular accident (CVA) is a neurological injury to the brain caused by either 
ischemic or hemorrhagic insult. When a CVA is caused by ischemia and the patient has 
debilitating neurological deficits, thrombolytics such as tPA is recommended as long as the 
patient does not have any absolute contraindications. However, one of the primary indications 
to administer tPA is age > 18 years old. If a child is suffering an ischemic stroke, tPA use would be 
off-label and treatment should be coordinated with pediatric sub-specialists. Management is 
based on clinical experience of experts, recommendations of consensus guidelines, case studies 
and extrapolation from adult clinical trials.  
 
Figure 2:  CT Head with IV contrast showing complete occlusion of mid to distal 
M1 segment of right MCA.  
Figure 3:  3D reconstruction of the patients Circle of Willis which shows 
complete occlusion of the R MCA.  
